A population pharmacokinetic-pharmacogenetic analysis of atazanavir

AIDS Research and Human Retroviruses

Volumn 28, Issue 10, 2012, Pages 1227-1234

  Kile, Deidre A ^a   Mawhinney, Samantha ^b   Aquilante, Christina L ^c   Rower, Joseph E ^c   Castillo Mancilla, Jose R ^a   Anderson, Peter L ^c  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b Global Health and Health Disparities   (United States)

^c UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATAZANAVIR; ATAZANAVIR PLUS RITONAVIR; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; MULTIDRUG RESISTANCE PROTEIN 1; ORGANIC ANION TRANSPORTER 1; PREGNANE X RECEPTOR; RITONAVIR;

ABCB1 GENE; ABCG2 GENE; ADULT; AFRICAN AMERICAN; AGE; ARTICLE; BLOOD SAMPLING; CYP3A4 GENE; CYP3A5 GENE; DEMOGRAPHY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG METABOLISM; FEMALE; GENDER; GENE; GENETIC POLYMORPHISM; GENOTYPE; HAPLOTYPE; HUMAN; HUMAN EXPERIMENT; MALE; MORNING DOSAGE; NORMAL HUMAN; NR1I2 GENE; PHARMACOGENETICS; PRIORITY JOURNAL; RACE DIFFERENCE; SLCO1B1 GENE;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; AFRICAN AMERICANS; COST-BENEFIT ANALYSIS; CYTOCHROME P-450 CYP3A; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENOTYPE; HAPLOTYPES; HIV PROTEASE INHIBITORS; HUMANS; MALE; MIDDLE AGED; OLIGOPEPTIDES; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE; PYRIDINES; RITONAVIR; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84866696853     PISSN: 08892229     EISSN: 19318405     Source Type: Journal    
DOI: 10.1089/aid.2011.0378     Document Type: Article

References (28)

1. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. 1-239. Available at www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf
2. Horberg M, Klein D, Hurley L, et al.: Efficacy and safety of ritonavir-boosted and unboosted atazanavir among anti-retroviral-naive patients. HIV Clin Trials 2008;9(6):367-374.
3. Wempe MF and Anderson PL: Atazanavir metabolism according to CYP3A5 status: An in vitro-in vivo assessment. Drug Metab Dispos 2011;39(3):522-527.
4. Koudriakova T, Iatsimirskaia E, Utkin I, et al.: Metabolism of the human immunodeficiency virus protease inhibitors in-dinavir and ritonavir by human intestinal microsomes and expressed cytochrome P4503A4/3A5: Mechanism-based in-activation of cytochrome P4503A by ritonavir. Drug Metab Dispos 1998;26(6):552-561.
5. Malan DR, Krantz E, David N, Wirtz V, Hammond J, and McGrath D: Efficacy and safety of atazanavir, with or without ritonavir, as part of once-daily highly active anti-retroviral therapy regimens in antiretroviral-naive patients. J Acquir Immune Defic Syndr 2008;47(2):161-167.
6. Rodriguez Novoa S, Barreiro P, Rendon A, et al.: Plasma levels of atazanavir and the risk of hyperbilirubinemia are predicted by the 3435C/T polymorphism at the multidrug resistance gene 1. Clin Infect Dis 2006;42(2):291-295.
7. Siccardi M, D'Avolio A, Baietto L, et al.: Association of a single-nucleotide polymorphism in the pregnane X receptor (PXR 63396C/T) with reduced concentrations of unboosted atazanavir. Clin Infect Dis 2008;47(9):1222-1225.
8. Schipani A, Siccardi M, D'Avolio A, et al.: Population phar-macokinetic modeling of the association between 63396C/T pregnane X receptor polymorphism and unboosted atazana-vir clearance. Antimicrob Agents Chemother 2010;54(12): 5242-5250.
9. Anderson PL, Aquilante CL, Gardner EM, et al.: Atazanavir pharmacokinetics in genetically determined CYP3A5 ex-pressors versus non-expressors. J Antimicrob Chemother 2009;64(5):1071-1079.
10. Bousquet L, Roucairol C, Hembury A, et al.: Comparison of ABC transporter modulation by atazanavir in lymphocytes and human brain endothelial cells: ABC transporters are involved in the atazanavir-limited passage across an in vitro human model of the blood-brain barrier. AIDS Res Hum Retroviruses 2008;24(9):1147-1154.
11. Kimchi-Sarfaty C, Oh JM, Kim IW, et al.: A "silent" polymorphism in the MDR1 gene changes substrate specificity. Science 2007;315(5811):525-528.
12. Kivistö K and Niemi M: Influence of drug transporter polymorphisms on pravastatin pharmacokinetics in humans. Pharm Res 2007;24(2):239-247.
13. Kohlrausch FB, De Cássia Estrela R, Barroso PF, and Suarez-Kurtz G: The impact of SLCO1B1 polymorphisms on the plasma concentration of lopinavir and ritonavir in HIV-in-fected men. Br J Clin Pharmacol 2010;69(1):95-98.
14. Lamba J, Lamba V, Strom S, Venkataramanan R, and Schuetz E: Novel single nucleotide polymorphisms in the promoter and intron 1 of human pregnane X receptor/NR1I2 and their association with CYP3A4 expression. Drug Metab Dispos 2008;36(1):169-181.
15. Lamba JK, Lin YS, Schuetz EG, and Thummel KE: Genetic contribution to variable human CYP3A-mediated metabolism. Adv Drug Deliv Rev 2002;54(10):1271-1294.
16. Lubomirov R, di Iulio J, Fayet Al, et al.: ADME pharmaco-genetics: investigation of the pharmacokinetics of the anti-retroviral agent lopinavir coformulated with ritonavir. Pharmacogenet Genom 2010;20(4):217-230.
17. Mizuarai S, Aozasa N, and Kotani H: Single nucleotide polymorphisms result in impaired membrane localization and reduced atpase activity in multidrug transporter ABCG2. Int J Cancer 2004;109(2):238-246.
18. Perera MA: The missing linkage: what pharmacogenetic associations are left to find in CYP3A? Expert Opin Drug Metab Toxicol 2010;6(1):17-28.
19. Beal S, Sheiner L, and Boeckmann A: NONMEM users guides. Ellicott City, MD: ICON Development Solutions; 1989-2006.
20. Wandel C, Witte JS, Hall JM, Stein CM, Wood AJ, and Wilkinson GR: CYP3A activity in African American and European American men: Population differences and functional effect of the CYP3A4 1B5'-promoter region polymorphism. Clin Pharmacol Ther 2000;68(1):82-91.
21. Yasuda SU, Zhang L, and Huang SM. The role of ethnicity in variability in response to drugs: focus on clinical pharmacology studies. Clin Pharmacol Ther 2008;84(3):417-423.
22. King JR, Kakuda TN, Paul S, Tse MM, Acosta EP, and Becker SL: Pharmacokinetics of saquinavir with atazanavir or low-dose ritonavir administered once daily (ASPIRE I) or twice daily (ASPIRE II) in seronegative volunteers. J Clin Pharmacol 2007;47(2):201-208.
23. Greenblatt DJ and von Moltke LL: Gender has a small but statistically significant effect on clearance of CYP3A substrate drugs. J Clin Pharmacol 2008;48(11):1350-1355.
24. O'mara E, Randall D, Stoltz RR, Geraldes M, and Mummaneni V: BMS-232632: A Prospective Study of Age and Gender Effects on the Single-Dose Pharmacokinetics in Healthy Volunteers [Abstract 350]. Paper presented at the 1st IAS Conference on HIV Pathogenesis and Treatment, July 7-11, 2001, Buenos Aires, Argentina.
25. Colombo S, Buclin T, Cavassini M, et al.: Population phar-macokinetics of atazanavir in patients with human immunodeficiency virus infection. Antimicrob Agents Chemother 2006;50(11):3801-3808.
26. Dickinson L, Boffito M, Back D, et al.: Population pharma-cokinetics of ritonavir-boosted atazanavir in HIV-infected patients and healthy volunteers. J Antimicrob Chemother 2009;63(6):1233-1243.
27. Barrail-Tran A, Mentre F, Cosson C, et al.: Influence of alpha-1 glycoprotein acid concentrations and variants on atazanavir pharmacokinetics in HIV-infected patients included in the ANRS 107 Trial. Antimicrob Agents Chemother 2010;54(2):614-619.
28. Zhu L, Persson A, Mahnke L, et al.: Effect of low-dose omeprazole (20mg daily) on the pharmacokinetics of multiple-dose atazanavir with ritonavir in healthy subjects. J Clin Pharmacol 2011 2011;51(3):368-377.